The patent battle over CRISPR-Cas9 technology has gone on for longer than a decade, but continues to wind its way through the courts. The global CRISPR-Cas9 gene-editing market size is expected to grow to $14.65 billion by 2032, and Professor Jacob Sherkow told BioSpace that companies seeking to license the technology may be content to wait and see how the patent battle settles rather than rushing to pay now. “If you get that wrong, that is a lot of money you set on fire,” Sherkow said.
Read the full article online.